A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
↧